Earnings History Data for Apellis Pharmaceuticals, Inc. (APLS) - NYSE NASDAQ

To lookup another company type a stock symbol and press 'Go'. The overview will show the earnings release info that is available in TheStockCatalyst database for the company.

For historic stock the Extended Hours price data shown are from just before market open on the day of release for premarket earnings releases and of the day after release for afterhours earnings releases. The normal price data is from just before market close on the days of release for premarket releases and the day after release for afterhours releases.

See the full list of available companies here.

Apellis Pharmaceuticals, Inc.

Apellis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. It focused on the development of novel therapeutic compounds to treat disease through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade. Apellis Pharmaceuticals, Inc. is based in CRESTWOOD, United States.

Release Date	Time	Est. Time	Symbol	Name	Market Cap (M)	Rep. EPS	Est. EPS	Last years EPS	SeekingAlpha Headline	Price	Change	Ext. Hours Price	Ext. Hours Change	52 Week Range	Volume	Avg. Volume	Ext. Hours Volume
05-11-2024	PM		APLS	Apellis Pharmaceuticals, Inc.	3,320	-0.46	-0.32	-1.17	Apellis Pharmaceuticals GAAP EPS of -$0.46 misses by $0.15, revenue of $196.83M misses by $2.99M [11/5/2024 7:06 AM]	28.05	-0.50 (-1.77%)	25.45	-3.11 (-10.89%)	24.34 - 73.80	8,064,960	3,030,000	418,575
Apellis Pharmaceuticals Q3 2024 Earnings Preview [11/4/2024 2:37 PM] Apellis Pharmaceuticals GAAP EPS of -$0.46 misses by $0.15, revenue of $196.83M misses by $2.99M [11/5/2024 7:06 AM] Apellis drops as disappointing Syfovre sales drive Q3 miss [11/5/2024 9:28 AM] Apellis Pharmaceuticals Reports Third Quarter 2024 Financial Results [2024-11-05 07:05AM] Apellis Pharmaceuticals Inc (APLS) Q3 2024 Earnings Report Preview: What to Look For [Nov-04-24 07:04AM]
01-08-2024	PM		APLS	Apellis Pharmaceuticals, Inc.	4,760	-0.28	-0.33	-1.02	Apellis Pharmaceuticals GAAP EPS of -$0.30 beats by $0.02, revenue of $199.69M beats by $8.38M [8/1/2024 7:10 AM]	35.95	-3.65 (-9.20%)	38.00	-1.60 (-4.04%)	19.83 - 73.80	4,896,664	1,450,000	77,913
Apellis Pharmaceuticals Q2 2024 Earnings Preview [7/31/2024 12:07 PM] Apellis Pharmaceuticals GAAP EPS of -$0.30 beats by $0.02, revenue of $199.69M beats by $8.38M [8/1/2024 7:10 AM]
07-05-2024	PM		APLS	Apellis Pharmaceuticals	5,760	-0.54	-0.54	0.00	Apellis Pharmaceuticals GAAP EPS of -$0.54 misses by $0.09, revenue of $172.3M beats by $8.04M [5/7/2024 7:16 AM]	43.81	-5.00 (-10.24%)	47.05	-1.76 (-3.61%)	19.83 - 94.75	4,319,244	1,910,000	7,677
Apellis Pharmaceuticals GAAP EPS of -$0.54 misses by $0.09, revenue of $172.3M beats by $8.04M [5/7/2024 7:16 AM] Apellis Pharmaceuticals Q1 2024 Earnings Preview [5/6/2024 10:39 AM]
27-02-2024	PM		APLS	Apellis Pharmaceuticals, Inc.	8,110	-0.73	-0.66	-1.50	Apellis Pharmaceuticals GAAP EPS of -$0.73 misses by $0.04, revenue of $146.4M beats by $2.81M [2/27/2024 7:06 AM]	69.39	-2.34 (-3.26%)	69.00	-2.73 (-3.81%)	19.83 - 94.75	2,256,136	1,080,000	20,112
Apellis Pharmaceuticals Q4 2023 Earnings Preview [2/26/2024 11:50 AM] Apellis Pharmaceuticals GAAP EPS of -$0.73 misses by $0.04, revenue of $146.4M beats by $2.81M [2/27/2024 7:06 AM]
01-11-2023	PM		APLS	Apellis Pharmaceuticals, Inc.	5,640	-1.17	-0.86	-1.75	Apellis Pharmaceuticals GAAP EPS of -$1.17 misses by $0.31, revenue of $110.4M beats by $11.67M [11/1/2023 7:10 AM]	49.92	1.27 (2.60%)	46.02	-2.64 (-5.43%)	19.83 - 94.75	2,590,741	1,550,000	152,422
Apellis Pharmaceuticals Q3 2023 Earnings Preview [10/31/2023 12:40 PM] Apellis Pharmaceuticals GAAP EPS of -$1.17 misses by $0.31, revenue of $110.4M beats by $11.67M [11/1/2023 7:10 AM]
31-07-2023	PM		APLS	Apellis Pharmaceuticals, Inc.	3,740	-1.02	-1.35	-1.46	Apellis Pharmaceuticals GAAP EPS of -$1.02 beats by $0.30, revenue of $94.9M beats by $23.78M [7/31/2023 7:07 AM]	25.68	-6.34 (-19.80%)	31.17	-0.85 (-2.65%)	24.97 - 94.75	18,413,652	10,890,000	1,933,764
Apellis Pharmaceuticals GAAP EPS of -$1.02 beats by $0.30, revenue of $94.9M beats by $23.78M [7/31/2023 7:07 AM] Biggest stock movers today: Nikola, XPeng, SoFi Technologies and more [7/31/2023 10:29 AM] Apellis off 18% despite reassurance of safety of vision drug, earnings [7/31/2023 11:23 AM]
04-05-2023	AH	4:05 PM ET (May 4)	APLS	Apellis Pharmaceuticals, Inc.	9,660	-1.56	-1.42	-1.42	Apellis Pharmaceuticals GAAP EPS of -$1.56 misses by $0.10, revenue of $44.84M beats by $18.74M [5/4/2023 4:45 PM]	93.03	8.66 (10.26%)	92.25	7.88 (9.34%)	33.32 - 94.45	3,774,072	1,850,000	45,917
Apellis Pharmaceuticals GAAP EPS of -$1.56 misses by $0.10, revenue of $44.84M beats by $18.74M [5/4/2023 4:45 PM]
21-02-2023	AH	4:05 PM ET (Feb 21)	APLS	Apellis Pharmaceuticals	6,136	-1.50	-1.65	0.00	Apellis Pharmaceuticals GAAP EPS of -$1.50 beats by $0.06, revenue of $22.66M misses by $1.86M [2/21/2023 4:57 PM]	66.25	7.75 (13.25%)	61.00	2.50 (4.27%)	33.32 - 70.00	4,682,521	1,930,000	49,510
Apellis Pharmaceuticals to raise $300M in stock and warrants offering [2/22/2023 8:15 AM] Apellis Pharmaceuticals GAAP EPS of -$1.50 beats by $0.06, revenue of $22.66M misses by $1.86M [2/21/2023 4:57 PM]
07-11-2022	AH	4:05 PM ET (Nov 7)	APLS	Apellis Pharmaceuticals, Inc.	6,600	-1.75	-1.48	-2.28	Apellis Pharmaceuticals GAAP EPS of -$1.75 misses by $0.29, revenue of $22.05M beats by $0.46M [11/7/2022 4:24 PM]	47.24	-0.38 (-0.80%)	48.10	0.48 (1.01%)	33.08 - 70.00	2,455,114	1,790,000	66,894
Apellis Pharmaceuticals GAAP EPS of -$1.75 misses by $0.29, revenue of $22.05M beats by $0.46M [11/7/2022 4:24 PM] Apellis Pharma Crashes On Unexpected Delay For Eye Drug, Taking A Key Rival With It [Nov-04-22 04:24PM] Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) [Nov-04-22 04:05PM] 15 Best Strong Buy Stocks to Invest In [Nov-04-22 12:47PM] Why Are Apellis Pharmaceuticals Shares Falling Today? [Nov-04-22 12:12PM] Is a Surprise Coming for Apellis (APLS) This Earnings Season? [Nov-04-22 08:34AM] Apellis Pharmaceuticals Reports Third Quarter 2022 Financial Results [Nov-07-22 04:05PM] Apellis Pharmaceuticals, Inc. (APLS) Reports Q3 Loss, Tops Revenue Estimates [Nov-07-22 05:25PM]
08-08-2022	AH	4:05 PM ET (Aug 8)	APLS	Apellis Pharmaceuticals, Inc.	5,620	-1.46	-1.43	-2.72	Apellis Pharmaceuticals GAAP EPS of -$1.46 misses by $0.09, revenue of $16.32M misses by $0.63M [8/8/2022 4:15 PM]	64.25	1.92 (3.08%)	59.01	-3.32 (-5.33%)	27.50 - 67.74	878,629	1,240,000	1,678
Apellis Pharmaceuticals GAAP EPS of -$1.46 misses by $0.09, revenue of $16.32M misses by $0.63M [8/8/2022 4:15 PM] Apellis Pharmaceuticals Reports Second Quarter 2022 Financial Results [Aug-08-22 04:05PM]
04-05-2022	AH	4:05 PM ET (May 4)	APLS	Apellis Pharmaceuticals	4,635	-1.42	-1.36	0.00	Apellis Pharmaceuticals GAAP EPS of -$1.42 misses by $0.12, revenue of $12.1M misses by $0.52M [5/4/2022 4:13 PM]	44.43	-1.52 (-3.31%)	41.36	-4.59 (-9.99%)	27.50 - 73.00	727,856	930,000	8,203
Apellis Pharmaceuticals GAAP EPS of -$1.42 misses by $0.12, revenue of $12.1M misses by $0.52M [5/4/2022 4:13 PM] Apellis Announces Dr. Peter Hillmen, Renowned Hematologist and PNH Expert, to Join Company [May-03-22 07:00AM] Apellis Pharmaceuticals Reports First Quarter 2022 Financial Results [May-04-22 04:05PM] Apellis Pharmaceuticals, Inc. (APLS) Reports Q1 Loss, Tops Revenue Estimates [May-04-22 06:15PM] Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Analysts Just Trimmed Their Revenue Forecasts By 16% [May-05-22 10:04AM]
28-02-2022	AH	4:00 PM ET (Feb 28)	APLS	Apellis Pharmaceuticals, Inc.	4,220	-1.61	-1.32	0.93	Apellis Pharmaceuticals GAAP EPS of -$1.61 misses by $0.12, revenue of $60.29M beats by $51.51M [2/28/2022 4:31 PM]	44.64	2.11 (4.96%)	42.53	0.0 (0.00%)	27.50 - 73.00	1,184,474	680,000	12,360
Apellis Pharmaceuticals GAAP EPS of -$1.61 misses by $0.12, revenue of $60.29M beats by $51.51M [2/28/2022 4:31 PM] Apellis Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results [Feb-28-22 04:05PM] Apellis Pharmaceuticals, Inc. (APLS) Reports Q4 Loss, Tops Revenue Estimates [Feb-28-22 05:45PM] Apellis (APLS) Q4 Loss Widens, Revenues Surpass Estimates [Mar-01-22 09:34AM]
08-11-2021	AH	4:00 PM ET (Nov 8)	APLS	Apellis Pharmaceuticals, Inc.	2,990	-2.28	-1.73	-1.79	Apellis Pharmaceuticals EPS misses by $0.57, misses on revenue [11/8/2021 4:04 PM]	37.36	3.67 (10.89%)	33.00	-0.69 (-2.05%)	27.50 - 73.00	1,990,143	880,000	85,601
Apellis Pharmaceuticals EPS misses by $0.57, misses on revenue [11/8/2021 4:04 PM] Apellis Pharmaceuticals Reports Third Quarter 2021 Financial Results [Nov-08-21 04:01PM] Apellis Pharmaceuticals, Inc. (APLS) Reports Q3 Loss, Tops Revenue Estimates [Nov-08-21 05:15PM] Apellis' (APLS) Q3 Loss Widens, Revenues Surpass Estimates [Nov-09-21 10:45AM]
09-08-2021	AH	4:00 PM ET (Aug 9)	APLS	Apellis Pharmaceuticals, Inc.	5,590	-2.72	-1.70	-1.57	Apellis Pharmaceuticals EPS misses by $1.03, beats on revenue [8/9/2021 4:19 PM]	59.90	-2.10 (-3.40%)	62.00	0.0 (0.00%)	26.38 - 73.00	615,635	720,000	196,848
Apellis Pharmaceuticals EPS misses by $1.03, beats on revenue [8/9/2021 4:19 PM] Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) [Aug-06-21 04:05PM] Apellis Pharmaceuticals Reports Second Quarter 2021 Financial Results [Aug-09-21 04:01PM] Apellis Pharmaceuticals, Inc. (APLS) Reports Q2 Loss, Misses Revenue Estimates [Aug-09-21 05:25PM] Apellis' (APLS) Q2 Earnings & Revenues Fall Shy of Estimates [Aug-10-21 03:36PM]
28-04-2021	AH	4:00 PM ET (Apr 28)	APLS	Apellis Pharmaceuticals, Inc.	3,630	-2.32	-1.69	-2.29	Apellis Pharmaceuticals EPS misses by $0.69 [4/28/2021 4:03 PM]	48.39	3.09 (6.82%)	45.30	0.0 (0.00%)	25.49 - 58.47	721,832	580,000	9,920
Apellis Pharmaceuticals EPS misses by $0.69 [4/28/2021 4:03 PM] Apellis Pharmaceuticals, Inc. (APLS) Upgraded to Buy: Here's Why [Apr-28-21 12:00PM] Apellis Pharmaceuticals, Inc. to Host Earnings Call [Apr-28-21 02:30PM] Apellis Pharmaceuticals Reports First Quarter 2021 Financial Results [Apr-28-21 04:01PM] Apellis Pharmaceuticals, Inc. (APLS) Reports Q1 Loss, Misses Revenue Estimates [Apr-28-21 05:25PM] Apellis' (APLS) Q1 Earnings Miss, Pegcetacoplan in Focus [Apr-29-21 08:41AM]
25-02-2021	AH	4:10 PM ET (Feb 25)	APLS	Apellis Pharmaceuticals, Inc.	3,660	0.93	-0.47	-1.70	Apellis Pharmaceuticals EPS beats by $1.38, beats on revenue [2/25/2021 4:02 PM]	48.37	3.32 (7.37%)	46.20	1.15 (2.55%)	16.85 - 58.47	611,867	465,679	7,943
Apellis Pharmaceuticals EPS beats by $1.38, beats on revenue [2/25/2021 4:02 PM] Apellis' (APLS) Q4 Earnings Rise Y/Y, Pegcetacoplan in Focus [Feb-26-21 10:14AM] Apellis Pharmaceuticals, Inc. (APLS) Tops Q4 Earnings and Revenue Estimates [Feb-25-21 05:45PM] Apellis Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results [Feb-25-21 04:01PM]
02-11-2020	PM		APLS	Apellis Pharmaceuticals, Inc.	2,410	-1.79	-1.53	-1.10	Apellis Pharmaceuticals EPS misses by $0.21 [11/2/2020 7:14 AM]	36.95	3.48 (10.40%)	33.47	0.0 (0.00%)	16.85 - 45.04	983,650	547,945	11,746